One key reason why circulating tumor cells detection is suitable for inclusion in the daily tracking process is that the sampling threshold is relatively low. Taking Good Future's current process as an example, a 2 mL blood sample can be used to start the test. There is no need to fast beforehand, and there is no need to bear the risks of radiation exposure or contrast agents that are common in imaging examinations. It is easier to arrange for regular follow-ups.
After the sample enters the laboratory, pre-processing, cell enrichment, immunofluorescence staining, automatic microscopic photography and image interpretation are completed in sequence. These steps are not separate single-point operations, but are connected by a systematic process. The purpose is to make the final output not just numerical values, but cell images and interpretation basis that can be reviewed back.
Good Future's inspection reports are usually delivered within 5 business days. In addition to the basic results, the content will also be paired with cell images, marker performance, and communicable interpretation information, so that the results are not just a judgment within the laboratory, but also content that can be further read and discussed by the clinical side, the subjects, and their families.
For situations that require risk assessment, treatment tracking, or postoperative monitoring, what is really valuable is "being able to understand what is happening in the sample." Therefore, the overall process from a small amount of inspection to a readable report is the difference between Good Future's testing service and general single-point numerical output.
